Zealand Pharma: starts phase 3 trial with dasiglucagon.
(CercleFinance.com) - Zealand Pharma said on Monday that it has started a multinational phase 3 clinical trial on dasiglucagon for the treatment of severe hypoglycemia in diabetes.
The aim of the trial - conducted in four countries (Austria, Germany, Canada and the US) - is to evaluate the immunogenicity of repeated single doses of dasiglucagon following subcutaneous administration to patients with type-1 diabetes, as well as the drug's effect, safety, tolerability.
Dasiglucagon will be compared with Novo Nordisk's GlucaGen.
"The timing of phase III trials for dasiglucagon as a rescue therapy is fully respected since it was expected to take place in the second half of 2017," Bryan Garnier analysts commented this morning.
The broker maintains a "buy" rating on the share, with a "fair value" of 210 Danish kronor.
The Zealand Pharma stock is currently up 0.4% at 131 Danish kronor this morning on the Nasdaq Nordic market.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The aim of the trial - conducted in four countries (Austria, Germany, Canada and the US) - is to evaluate the immunogenicity of repeated single doses of dasiglucagon following subcutaneous administration to patients with type-1 diabetes, as well as the drug's effect, safety, tolerability.
Dasiglucagon will be compared with Novo Nordisk's GlucaGen.
"The timing of phase III trials for dasiglucagon as a rescue therapy is fully respected since it was expected to take place in the second half of 2017," Bryan Garnier analysts commented this morning.
The broker maintains a "buy" rating on the share, with a "fair value" of 210 Danish kronor.
The Zealand Pharma stock is currently up 0.4% at 131 Danish kronor this morning on the Nasdaq Nordic market.
Copyright (c) 2017 CercleFinance.com. All rights reserved.